Slowing down the immune system when in overdrive
Media Release: 11 February 2014
Many people suffer from chronic inflammation because their immune systems overreact to ‘self’ tissue. Sydney scientists believe that a small molecule known as Interleukin 21 is a promising therapeutic target in such cases.
Interleukin 21 (IL-21) is one of a group of chemical messengers known as ‘cytokines’, which affect the behaviour of immune cells. IL-21 is already well known to play an important role in autoimmune diseases such as Sjögren's syndrome and type 1 diabetes.
The current study shows how much IL-21 contributes to inflammation. It also shows how important it is to remove IL-21 to reduce inflammation, even where there are other severe immune defects present.
Undertaken at Sydney’s Garvan Institute of Medical Research, researchers used mice genetically deficient in another cytokine (IL-2), a well-established mouse model of autoimmunity. In some mice, the IL-21 cell surface receptor was also genetically removed. In these mice, inflammatory disease was much less severe, demonstrating that IL-21 contributes to fatal inflammatory disease.
Immunologists Associate Professor Cecile King and Dr Alexis Vogelzang, in collaboration with bioinformatics experts Drs Marcel Dinger and Brian Gloss, combined cellular analysis and RNA sequencing to compare genes expressed in the disease model with those expressed in healthy immune cells. The study confirmed that IL-21 is one of the most highly expressed genes in autoimmune disease.
The findings are published in the Journal of Immunology, now online.
“RNA sequencing is an unbiased way of determining differential expression of genes, and this data revealed the proinflammatory gene signature of autoimmune disease and confirmed the extent to which IL-21 is elevated in the absence of IL-2,” said Associate Professor King.
“When you remove the IL-2 gene, another group of very calming immune cells known as ‘T regulatory cells’ also disappear – because T regulatory cells express high levels of the IL-2 receptor and are IL-2 dependent. Without T regulatory cells, the immune system goes haywire and the body starts attacking itself.”
“Under these conditions, IL-21 kicks in and make things much worse.”
“When IL-21 is blocked, the huge inflammatory response is greatly subdued, although not entirely eliminated.”
“There are many people with chronic inflammation caused by defective T cell regulation, and this research suggests that blocking IL-21 with drugs might help them.”
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent's Hospital in Sydney, it is now one of Australia's largest medical research institutions with over 600 scientists, students and support staff. Garvan’s main research areas are: Cancer, Diabetes & Obesity, Immunology and Inflammation, Osteoporosis and Bone Biology, and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.
Science Communications Manager
Garvan Institute of Medical Research
+61 2 9295 8128
+61 434 071 326